Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort – The Tumor Anemia Registry. 7. Juni 2016 Steinmetz, T., Schröder, J., Plath, M., Link, H., Vogt, M., Frank, M., Marschner, N., 2016. Anemia 2016, e8057650. doi:10.1155/2016/8057650 Abstract Patient-reported outcomes in elderly bevazizumab-treated primary ovarian cancer patients: OTILIA study on behalf of the north-eastern german society of gynaecological oncology. Sehouli, J., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Mustea,… Weiterlesen Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C.-C., Koehler, A., Depenbusch, R., Busies, S., Hegewisch-Becker, S., 2016. Breast Cancer Res Treat 156, 97–107. Weiterlesen